Wells Fargo & Company Issues Positive Forecast for STAAR Surgical (NASDAQ:STAA) Stock Price

STAAR Surgical (NASDAQ:STAA) had its price target lifted by Wells Fargo & Company from $16.00 to $25.00 in a research note released on Friday,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Several other research firms have also recently weighed in on STAA. Mizuho upped their price target on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a report on Thursday. Piper Sandler upped their price target on shares of STAAR Surgical from $16.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday. Jefferies Financial Group reduced their price target on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a report on Wednesday, January 28th. Weiss Ratings cut shares of STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Finally, Morgan Stanley initiated coverage on shares of STAAR Surgical in a report on Friday, January 16th. They issued an “underweight” rating and a $13.00 price target for the company. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $27.81.

STAAR Surgical Stock Up 0.2%

Shares of NASDAQ STAA opened at $32.07 on Friday. The stock has a market cap of $1.60 billion, a P/E ratio of -74.58 and a beta of 1.20. The firm has a 50 day moving average price of $22.74 and a 200 day moving average price of $22.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.74 and a current ratio of 5.12. STAAR Surgical has a 52-week low of $15.59 and a 52-week high of $35.87.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. The firm had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The business’s revenue for the quarter was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.10) earnings per share. Analysts expect that STAAR Surgical will post -0.03 EPS for the current year.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. acquired 316,017 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the transaction, the director directly owned 16,123,842 shares in the company, valued at $300,064,699.62. This trade represents a 2.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have acquired a total of 670,213 shares of company stock valued at $12,266,249 over the last 90 days. Insiders own 39.90% of the company’s stock.

Institutional Trading of STAAR Surgical

Institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its position in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 1,016 shares in the last quarter. Ascentis Independent Advisors bought a new stake in shares of STAAR Surgical in the first quarter worth $77,000. Tower Research Capital LLC TRC raised its position in STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 4,673 shares in the last quarter. Russell Investments Group Ltd. raised its position in STAAR Surgical by 9,928.9% during the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after acquiring an additional 4,468 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in STAAR Surgical during the third quarter worth $199,000. Institutional investors own 96.70% of the company’s stock.

Key Stories Impacting STAAR Surgical

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical beat Q1 earnings and revenue expectations, with the business swinging to a profit and showing strong year-over-year improvement. Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Wedbush upgraded STAA to Outperform and lifted its price target to $40, citing improving prospects tied to a China recovery. STAAR Surgical was upgraded by Wedbush
• Positive Sentiment: Mizuho also turned more constructive on the stock with a higher price target, reflecting better earnings momentum and outlook expectations. Mizuho Issues Positive Forecast for STAAR Surgical Stock Price
• Positive Sentiment: Commentary around the earnings call highlighted China strength, cost discipline, and stabilizing inventory as drivers of the turnaround. Staar Surgical Signals Sharp Turnaround Amid China Strength
• Neutral Sentiment: Wells Fargo raised its price target to $25 but kept an Equal Weight rating, signaling some caution despite the recent rally. STAAR Surgical had its price target raised by Wells Fargo
• Negative Sentiment: Some analysts still see limited visibility into STAAR Surgical’s 2026 outlook, and a new risk disclosure added to uncertainty around future performance and valuation. Staar Surgical Faces Heightened Uncertainty

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.